BRAF Inhibitor-Associated Granulomatous Dermatitis: A Report of 3 Cases
| Autor: | Rishika Sinha, Shilan Jmor, Eugene Liat Hui Ong, Louise Fearfield |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Proto-Oncogene Proteins B-raf
medicine.medical_specialty Skin Neoplasms Time Factors BRAF inhibitor Biopsy Antineoplastic Agents Dermatology Asymptomatic Pathology and Forensic Medicine 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine medicine Humans Vemurafenib Adverse effect Melanoma Protein Kinase Inhibitors Skin Granuloma medicine.diagnostic_test business.industry General Medicine Middle Aged medicine.disease Treatment Outcome Female Drug Eruptions medicine.symptom Granulomatous Dermatitis business medicine.drug |
| Zdroj: | The American Journal of dermatopathology. 41(3) |
| ISSN: | 1533-0311 |
| Popis: | Cutaneous toxicities associated with BRAF inhibitor treatment in patients with metastatic melanoma have been well described. We present a rare association of granulomatous dermatitis in association with the BRAF inhibitor vemurafenib. Three patients with metastatic melanoma all presented with asymptomatic papular eruptions 8-21 months into vemurafenib therapy. Skin biopsies confirmed the diagnosis of granulomatous dermatitis. Other causes of granulomatous dermatitis including infectious agents and sarcoid were excluded. Treatment with potent topical and oral steroids improved the eruptions, but only after the cessation of vemurafenib did all 3 cases of granulomatous dermatitis completely resolve within 2 weeks. It is important to recognize that this association, unlike most other BRAF inhibitor-related skin toxicities, can occur many months after commencement of therapy and that vemurafenib treatment can be continued without clinically significant adverse effects. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|